vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i4.381vsp-476Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSКЛИНИЧЕСКИЙ СЛУЧАЙ ПРИМЕНЕНИЯ ТОЦИЛИЗУМАБА У ПАЦИЕНТА С СИСТЕМНЫМ ЮВЕНИЛЬНЫМ ИДИОПАТИЧЕСКИМ АРТРИТОМA HISTORY CASE OF TOCILIZUMAB USAGE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITISДенисоваР. В.DenisovaR. V.

Rina Denisova, Candidate of Medical Science, senior research associate of rheumatologic department

denisovarv@yandex.ruАлексееваЕ. И.AlexeevaE. I.alekatya@ya.ruСлепцоваТ. В.SleptsovaT. V.alekatya@ya.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health, RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health, RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian Federation201219072012114Вопросы современной педиатрии187192Copyright © Денисова Р.В., Алексеева Е.И., Слепцова Т.В., 20122012Денисова Р.В., Алексеева Е.И., Слепцова Т.В.Denisova R.V., Alexeeva E.I., Sleptsova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/476

В статье приведен случай успешного применения препарата моноклональных антител к интерлейкину 6 тоцилизумаба при тяжелом системном варианте ювенильного идиопатического артрита, характеризующемся неэффективностью стандартной противоревматической терапии. Лечение тоцилизумабом в короткие сроки обеспечило быстрое снижение активности болезни, восстановление функции периферических суставов, повышение качества жизни пациента. Препарат предотвратил неуклонно прогрессирующую инвалидизацию больного и индуцировал развитие клинико-лабораторной ремиссии заболевания.

детисистемный ювенильный идиопатический артриттоцилизумабchildrensystemic juvenile idiopathic arthritistocilizumabReferencesCassidy J. T., Petty R. E. Juvenile idiopathic arthritis / In: Cassidy J. T., Petty R. E. (eds). Textbook of pediatric rheumatology, 5th edn. Philadelphia: WB Saunders. 2005.Cassidy J. T., Petty R. E. Juvenile idiopathic arthritis / In: Cassidy J. T., Petty R. E. (eds). Textbook of pediatric rheumatology, 5th edn. Philadelphia: WB Saunders. 2005.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8 (5): 14–25.Алексеева Е. И., Валиева С. И., Бзарова Т. М. Эффективность и безопасность повторных курсов лечения ритуксимабом тяжелого рефрактерного ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2009; 8 (5): 14–25.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общ. ред. акад. РАМН, проф. Баранова А. А. М. 2007. 368 с.Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников / под общ. ред. акад. РАМН, проф. Баранова А. А. М. 2007. 368 с.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–481.Kelly A., Ramanan A. V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 2007; 19: 477–481.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr. 2006; 95 (Suppl.): 38–41.Cortis E., Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr. 2006; 95 (Suppl.): 38–41.Veldhuis G. J., Willemse PH. B., Sleijfer D. T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.Veldhuis G. J., Willemse PH. B., Sleijfer D. T. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J. Clin. Oncol. 1995; 13: 2585–2593.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.Rothwell N. J., Busbridge N. J., Lefeuvre R. A., Hardwick A. J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can. J. Physiol. Pharmacol. 1991; 69: 1465–1469.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Castell J. V., Gomez-Lechon M. J., David M. et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988; 232: 347–350.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypo ferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Nemeth E., Rivera S., Gabayan V. et al. IL-6 mediates hypo ferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113: 1271–1276.Ikebuchi K., Wong G. G., Clark S. C. et al. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.Ikebuchi K., Wong G. G., Clark S. C. et al. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. Natl. Acad. Sci. USA. 1987; 84: 9035–9039.Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Kimura H., Ishibashi T., Uchida T. et al. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur. J. Immunol. 1990; 20: 1927–1931.Tsigos C., Papankolaou D. A., Defensor R. et al. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Tsigos C., Papankolaou D. A., Defensor R. et al. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66: 54–62.Heliovaara M. K., Teppo A. M., Karonen S. L. et al. Plasma IL-6 co ncentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes. Metab. 2005; 7: 729–736.Heliovaara M. K., Teppo A. M., Karonen S. L. et al. Plasma IL-6 co ncentration is inversely related to insulin sensitivity, and acute phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes. Metab. 2005; 7: 729–736.Cutolo M., Straub R. H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 2008; 7: 223–228.Cutolo M., Straub R. H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 2008; 7: 223–228.Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008; 181: 151–160.Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 2008; 181: 151–160.European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/ H-955-PI-en.pdf [accessed 2009 Mar 23]European Medicines Agency. RoActemra (tocilizumab): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandoes/PDFs/EPAR/RoActemra/ H-955-PI-en.pdf [accessed 2009 Mar 23]Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available from URL: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24]Chugai Pharmactutical Co. Actemra, a humanized antihuman IL-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [media release]. Available from URL: http://www.chugai-pharm.co.jp [accessed 2008 Sep 24]Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (II): 550.Imagawa T., Ozawa R., Miyamae T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyaticular course JIA with polyarticlar or olygoarticular onset. Ann. Rheum. Dis. 2007; 66 (II): 550.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (3): 715.Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (3): 715.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (3): 720.Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (3): 720.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68 (3): 118.Aoki C., Inaba Y., Ozawa R. Effects of tocilizumab on radiological findings in polyarticular juvenile idiopathic arthritis [OP-0145]. Ann. Rheum. Dis. 2009; 68 (3): 118.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (3): 506.Quartier P., Maire D., Souabni L. Efficacy and safety of tocilizumab in systemic onset juvenile idiopathic arthritis in french centers [FRI0462]. Ann. Rheum. Dis. 2009; 68 (3): 506.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (3): 719.Kaneko U., Imagawa T., Kishi T. Discrepancy between progression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (3): 719.Алексеева Е. И., Денисова Р. В., Валиева С. И. и др. Эффективность и безопасность тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2011; 10 (3): 24–31.Алексеева Е. И., Денисова Р. В., Валиева С. И. и др. Эффективность и безопасность тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2011; 10 (3): 24–31.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the phase 3 tender trial [OP0273]. Ann. Rheum. Dis. 2010; 69 (3): 146.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the phase 3 tender trial [OP0273]. Ann. Rheum. Dis. 2010; 69 (3): 146.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-Week Data [OP0006]. Ann. Rheum. Dis. 2011; 70 (3): 67.De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-Week Data [OP0006]. Ann. Rheum. Dis. 2011; 70 (3): 67.

The authors declare that there are no conflicts of interest present.